ESH AL 2018 | Immunotherapy clinical trial participation in R/R AML
Despite recent advancements in CAR T-cell therapy for the treatment of acute myeloid leukemia (AML), standard chemotherapy is still the mainstay of treatment for most AML patients. Here, Marion Subklewe, MD, from the LMU Hospital Munich, Munich, Germany, explores how patients suffering from relapsed/refractory AML with no suitable molecular targets, such as IDH, are less hesitant to participate in early clinical trials investigating the effects of novel AML therapies, despite the risks involved. Dr Subklewe also discusses how to manage the expectations of patients participating in these trials, by openly discussing the and the various risks involved, such as drug toxicity and low efficacy. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Get great new content delivered to your inboxSign up